India, Oct. 20 -- On Tuesday, Alpha Teknova (TKNO), a producer of reagents for therapies, vaccines and molecular diagnostics, released preliminary, unaudited third-quarter estimates and separately announced a proposed underwritten public offering of common stock.
For the quarter ended September 30, 2026, Teknova estimates revenue between the range of $12.5 million to $12.7 million, representing a growth of 19% to 21% compared to $10.5 million reported a year earlier.
Adjusted EBITDA is estimated at negative $1.2 million to negative $1 million, an improvement of at least 25%, supported by continued cost discipline. While adjusted EBITDA was negative $1.6 million in the prior year quarter.
Cash and short-term investments were estimated at ...